Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
260 participants
OBSERVATIONAL
2014-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
NCT01499433
An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
NCT01823289
Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease
NCT06819410
Voriconazole for IPA in Chinese Patients With COPD
NCT02234739
Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis
NCT06495905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Relevant case report forms are created in this study.
3. Basic information such as age,weight and height is recorded in selected cases.Clinical manifestations,risk factors,laboratory examination,imaging examination,etiological examination and histopathological examination are also recorded in selected cases by case report forms.In addition,antifungal treatment is recorded including name,dose,time of starting treatment and terminate treatment.Causes of terminate treatment and curative effect evaluation should be analysed.
4. Statistical analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Cryptococcal capsular polysaccharide antigen of blood or pleural effusion is positive
2. Cryptococcus（fungus culture) is discovered by lower respiratory tract specimens
3. Cryptococcus（pleural effusions culture) is discovered by pleural effusions collected under sterile condition
4. Cryptococcus（pus culture) is discovered by pus smear out of pulmonary infections in disseminated infection patients
5. Cryptococcus（blood culture) is discovered by microscopy of specimens of blood smear
6. Cryptococcus is discovered by culturing of the pathological tissue specimens in aseptic condition
7. Cryptococcal capsular budding yeast with inflammatory reaction is discovered by histopathological examination,cell pathology examination or microscopic examination in aseptic condition
Exclusion Criteria
2. Patients or their legal guardians request to withdraw the clinical research
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Beijing Chao Yang Hospital
OTHER
Ministry of Health, China
OTHER_GOV
Peking University Third Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
First Hospital of China Medical University
OTHER
Shengjing Hospital
OTHER
Second Hospital of Jilin University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Huadong Hospital
OTHER
Nanjing PLA General Hospital
OTHER
Fuzhou General Hospital
OTHER
Guangzhou Institute of Respiratory Disease
OTHER
Wuhan TongJi Hospital
OTHER
Xi'an Jiaotong University
OTHER
Guizhou Provincial People's Hospital
OTHER
Shenyang Military General Hospital
UNKNOWN
The Second Hospital of Hebei Medical University
OTHER
Xiangya Hospital of Central South University
OTHER
Fujian Provincial Hospital
OTHER
Fuzhou Pulmonary Hospital of Fujian
OTHER
Southwest Hospital, China
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
Wenzhou Medical University
OTHER
Shanghai Zhongshan Hospital
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Longyan City First Hospital
OTHER
Zhixin Liang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhixin Liang
Chinese Medical Association of respiratory diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhixin Liang, Doctor
Role: STUDY_DIRECTOR
Chinese PLA General Hospital
Zhen Wang
Role: PRINCIPAL_INVESTIGATOR
Beijing Chao Yang Hospital
Yanming Li
Role: PRINCIPAL_INVESTIGATOR
Ministry of Health, China
Lina Sun
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Jie Cao
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University General Hospital
Yunzhuo Chu
Role: PRINCIPAL_INVESTIGATOR
First Hospital of China Medical University
Zhijie Zhang
Role: PRINCIPAL_INVESTIGATOR
Shengjing Hospital
Yufen Jin
Role: PRINCIPAL_INVESTIGATOR
Second Hospital of Jilin University
Xiaobin Ma
Role: PRINCIPAL_INVESTIGATOR
Shandong Provincial Hospital
Yanping Zhu
Role: PRINCIPAL_INVESTIGATOR
Huadong Hospital
Xin Su
Role: PRINCIPAL_INVESTIGATOR
Nanjing PLA General Hospital
Guoxiang Lai
Role: PRINCIPAL_INVESTIGATOR
Fuzhou General Hospital
Feng Ye
Role: PRINCIPAL_INVESTIGATOR
Guangzhou Institute of Respiratory Disease
Shengdao Xiong
Role: PRINCIPAL_INVESTIGATOR
Wuhan TongJi Hospital
Lan Yang
Role: PRINCIPAL_INVESTIGATOR
Xi'an Jiaotong University
Hong Yu
Role: PRINCIPAL_INVESTIGATOR
Guizhou Provincial People's Hospital
wencheng Xue
Role: PRINCIPAL_INVESTIGATOR
Shenyang Military General Hospital
Yadong Yuan
Role: PRINCIPAL_INVESTIGATOR
The Second Hospital of Hebei Medical University
Chengping Hu
Role: PRINCIPAL_INVESTIGATOR
Xiangya Hospital of Central South University
Baosong Xie
Role: PRINCIPAL_INVESTIGATOR
Fujian Provincial Hospital
Xiaohong Chen
Role: PRINCIPAL_INVESTIGATOR
Fuzhou Pulmonary Hospital of Fujian
Xiangdong Zhou
Role: PRINCIPAL_INVESTIGATOR
Southwest Hospital, China
Wenjiang Ma
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Zhejiang University
Yuping Li
Role: PRINCIPAL_INVESTIGATOR
Wenzhou Medical University
Hongni Jiang
Role: PRINCIPAL_INVESTIGATOR
Shanghai Zhongshan Hospital
Wei Bai
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Nanchang University
Sucheng Zhong
Role: PRINCIPAL_INVESTIGATOR
Longyan City First Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LYN-316
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.